Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Rajamahanty, Srinivas ^a   Alonzo, Catherine ^a   Aynehchi, Shahrad ^a   Choudhury, Muhammad ^a   Konno, Sensuke ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BREFELDIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CYCLIN D; GROWTH INHIBITOR;

ANDROGEN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MEDIATOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BREFELDIN A; CELL CYCLE; CYCLIN D; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; DIHYDROTESTOSTERONE; G1 PHASE; GROWTH INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 77649322458     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-5     Document Type: Article

References (28)

1. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. P Singh G Hallur RK Anchoori O Bakare Y Kageyama SR Khan JT Isaacs, Prostate 2008 68 1570 1581
2. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Q Yang KM Fung WV Day BP Kropp HK Lin, Cancer Cell Int 2005 5 8 17
3. Androgen receptor in prostate cancer. CA Heinlein C Chang, Endocr Rev 2004 25 276 308
4. Transcriptional activation and nuclear targeting signals of the human androgen receptor. JA Simetal M Sar MV Lane FS French EM Wilson, J Biol Chem 1991 266 510 518
5. Prostate-specific antigen expression is regulated by an upstream enhancer. ER Schuur GA Henderson LA Kmetec JD Miller HG Lamparski DR Henderson, J Biol Chem 1996 271 7043 7051
6. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. MS Soloway H Matzkin, Cancer 1993 71 1083 1088
7. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. JP Moreau P Delavault J Blumberg, Clin Ther 2006 28 1485 1508
8. Antiviral activity of brefeldin A and verrucarin A. G Tamura K Ando S Suzuki A Takatsuki K Arima, J Antibiot 1968 21 160 161
9. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. T Fujiwara K Oda S Yokota A Takatsuki Y Ikehara, J Biol Chem 1988 263 18545 18552
10. Synthesis and anticancer activity of brefeldin A ester derivatives. NO Anadu VJ Davisson N Cushman, J Med Chem 2006 49 3897 3905
11. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. J Lippincott-Schwartz LC Yuan JS Bonifacino RD Klausner, Cell 1989 56 801 813
12. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. RG Shao T Shimizu Y Pommier, Exp Cell Res 1996 227 190 196
13. Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. H Guo TV Tittle H Allen RT Maziarz, Exp Cell Res 1998 245 57 68
14. Brefeldin A-induced apoptosis in prostatic cancer DU-145 cells: a possible p53-independent death pathway. JR Chapman H Tazaki C Mallouh S Konno, BJU Int 1999 83 703 708
15. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. E Wallen RG Sellers DM Peehl, J Urol 2000 164 836 841
16. The effects of brefeldin A (BFA) on cell cycle progression involving the modulation of the retinoblastoma protein (pRB) in PC-3 prostate cancer cells. JA Mordente S Konno Y Chen JM Wu H Tazaki C Mallouh, J Urol 1998 159 275 279
17. Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A. EA Sausville KLK Duncan A Senderowicz J Plowman PA Randazzo R Kahn L Malspeis MR Grever, Cancer J Sci Am 1996 2 52 58
18. The Pezcoller lecture: cancer cell cycles revised. CJ Sherr, Cancer Res 2000 60 3689 3695
19. LNCaP model of human prostatic carcinoma. JS Horoszewicz SS Leong E Kawinski JP Karr H Rosenthal TM Chu EA Mirand GP Murphy, Cancer Res 1983 43 1809 1818
20. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Trapman C Ris-Stalpers JA Van der Korput GG Kuiper PW Faber JC Romijn E Mulder AO Brinkmann, J Steroid Biochem Mol Biol 1990 37 837 842
21. Androgen binding as evidenced by a whole cell assay system using cultured canine prostatic epithelial cells. G Turcotte A Chapdelaine KD Roberts S Chevalier, J Steroid Biochem 1988 29 69 76
22. Biological actions of androgens. AD Mooradian JE Morley SG Korenman, Endocr Rev 1987 8 1 28
23. 1regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. KE Knudsen KC Arden WK Cavenee, J Biol Chem 1998 273 20213 20222
24. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. S Gupta T Hussain H Mukhtar, Arch Biochem Biophys 2003 410 177 185
25. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. A Tyagi C Agarwal R Agarwal, Mol Cancer Ther 2002 1 525 532
26. Synthesis and post-translational modification of the androgen receptor in LNCaP cells. GG Kuiper PE de Ruiter JA Grootegoed AO Brinkmann, Mol Cell Endocrinol 1991 80 65 73
27. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. L Sheflin B Keegan W Zhang SW Spaulding, Biochem Biophys Res Commun 2000 276 144 150
28. waf1 in ML-1 cells. K Fukuchi H Maruyama Y Takagi K Gomi, Biochim Biophys Acta 1999 1451 206 210